Stock 301301 YILI CHUANNING BIOTECHNOLOGY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Yili Chuanning Biotechnology Co.,Ltd.

Equities

301301

CNE100005WX0

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
13.3 CNY +0.45% Intraday chart for Yili Chuanning Biotechnology Co.,Ltd. -4.73% +58.33%
May. 14 Yili Chuanning Biotechnology Co.,Ltd. Approves Cash Dividend for the Year 2023 CI
Apr. 21 Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 19,894 18,672 29,621 - -
Enterprise Value (EV) 1 19,894 18,672 29,621 29,621 29,621
P/E ratio 42.6 x 20 x 22.5 x 19 x 16.6 x
Yield - - - - -
Capitalization / Revenue - 3.87 x 5.24 x 4.7 x 4.28 x
EV / Revenue - 3.87 x 5.24 x 4.7 x 4.28 x
EV / EBITDA - 11.2 x 13.8 x 12 x 10.8 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - 2.68 x 3.62 x 3.1 x 2.68 x
Nbr of stocks (in thousands) 2,222,800 2,222,800 2,227,160 - -
Reference price 2 8.950 8.400 13.30 13.30 13.30
Announcement Date 3/12/23 4/10/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 4,823 5,650 6,307 6,914
EBITDA 1 - 1,666 2,143 2,467 2,738
EBIT 1 - 1,121 1,555 1,846 2,098
Operating Margin - 23.25% 27.52% 29.27% 30.34%
Earnings before Tax (EBT) 1 - 1,118 1,550 1,842 2,093
Net income 1 411.5 940.6 1,314 1,558 1,771
Net margin - 19.5% 23.26% 24.71% 25.62%
EPS 2 0.2100 0.4200 0.5900 0.7000 0.8000
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/12/23 4/10/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 14.3% 16.1% 16.4% 16.1%
ROA (Net income/ Total Assets) - 9.16% 12.3% 14.3% 14.2%
Assets 1 - 10,265 10,684 10,898 12,474
Book Value Per Share 2 - 3.130 3.680 4.290 4.970
Cash Flow per Share 2 - - 0.6300 0.7900 0.9100
Capex 1 - 345 590 488 436
Capex / Sales - 7.15% 10.45% 7.74% 6.31%
Announcement Date 3/12/23 4/10/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Yili Chuanning Biotechnology Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
13.3 CNY
Average target price
10.6 CNY
Spread / Average Target
-20.30%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
YILI CHUANNING BIOTECHNOLOGY CO.,LTD. Stock Yili Chuanning Biotechnology Co.,Ltd.
+58.33% 4.09B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301301 Stock
  4. Financials Yili Chuanning Biotechnology Co.,Ltd.